For the quarter ending 2025-09-30, FHTX had $16,762K increase in cash & cash equivalents over the period. -$18,860K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -52,619 | - |
| Stock-based compensation expense | 2,733 | 5,425 |
| Depreciation and amortization expense | 852 | 1,678 |
| Impairment of long-lived assets | 0 | - |
| Noncash lease expense | 696 | 2,967 |
| Accretion of discount on marketable securities | 356 | 1,264 |
| Prepaid expenses and other current assets | -1,339 | -1,989 |
| Accounts payable | -110 | -463 |
| Accrued expenses and other liabilities | 1,157 | -388 |
| Operating lease liabilities | -1,169 | -4,633 |
| Deferred revenue | -8,153 | -13,509 |
| Net cash used in operating activities | -18,860 | -44,968 |
| Purchases of property and equipment | 0 | 50 |
| Purchases of marketable securities | 4,002 | 93,264 |
| Proceeds from maturities of marketable securities | 39,575 | 156,549 |
| Net cash provided by (used in) investing activities | 35,573 | 63,235 |
| Proceeds from offerings of common stock and pre-funded warrants, net of underwriting discounts and commissions | 0 | 0 |
| Payments of public offering costs | 0 | 0 |
| Proceeds from issuance of common stock upon exercise of stock options and employee stock purchase plan | 49 | 393 |
| Net cash provided by financing activities | 49 | 393 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 16,762 | 18,660 |
| Cash and cash equivalents at beginning of period | 57,162 | - |
| Cash and cash equivalents at end of period | 92,584 | - |
Foghorn Therapeutics Inc. (FHTX)
Foghorn Therapeutics Inc. (FHTX)